Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studiesYing Yuan, Kefeng Ding, Yueyin Pan et al.|Signal Transduction and Targeted Therapy|2025Cited by 14
Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRAS<sup>G12C</sup> mutation: Preliminary results from a pooled analysis of two phase I studies.Ying Yuan, Kefeng Ding, Yanhong Deng et al.|Journal of Clinical Oncology|2023Cited by 10